Research programme: cell based gene therapeutics - Synbal
Latest Information Update: 28 Dec 2022
At a glance
- Originator Synbal
- Developer BioLabs; Synbal
- Class Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 29 Nov 2018 Preclinical trials in Autoimmune disorders in USA (Parenteral)